文献速递基础与转化研究临床试验与 GCP组学、生物样本库与精准医学

输注后CAR TReg细胞识别对CD19-CAR治疗耐药的患者

Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy.
PubMed 文献 · Nat Med · 2022-09-12

研究对32例接受CD19-CAR治疗的大B细胞淋巴瘤患者进行单细胞蛋白组学分析,发现输注后第7天CD4+Helios+ CAR T细胞与疾病进展及较轻神经毒性相关,该群体为非克隆性并具T调节(TReg)细胞特征。验证队列支持该关联,将该亚群扩增与乳酸脱氢酶水平联合的模型预测持久临床缓解优于单特征模型。

要点

  • 输注后第7天CD4+Helios+ CAR T细胞与疾病进展和较轻神经毒性相关。
  • 该细胞群体为非克隆性,表现TReg细胞特征。
  • 联合CAR TReg扩增与乳酸脱氢酶的模型预测持久缓解优于单特征模型。

核心结论

  • CAR TReg细胞扩增是CAR T细胞治疗后缓解和毒性的新型生物标志物,并可能调节人体CAR T细胞反应。

研究设计与样本

  • 对32例接受CD19-CAR治疗的大B细胞淋巴瘤患者进行循环CAR T细胞的单细胞蛋白组学分析,并进行验证队列分析。

主要发现

  • 约60%接受靶向CD19的CAR T细胞治疗的大B细胞淋巴瘤患者出现疾病进展,神经毒性仍是挑战。
  • 输注后第7天CD4+Helios+ CAR T细胞与进展性疾病和较轻神经毒性相关。
  • 深度分析显示该群体为非克隆性并表现TReg细胞特征。
  • 验证队列分析支持较高CAR TReg细胞与临床进展和较轻神经毒性的关联。
  • 将该亚群扩增与作为肿瘤负荷替代指标的乳酸脱氢酶水平联合的模型,预测持久临床缓解优于仅依赖各特征单独的模型。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 60% of patients with large B cell lymphoma treated with chimeric antigen receptor (CAR) T cell therapies targeting CD19 experience disease progression, and neurotoxicity remains a challenge. Biomarkers associated with resistance and toxicity are limited. In this study, single-cell proteomic profiling of circulating CAR T cells in 32 patients treated with CD19-CAR identified that CD4+Helios+ CAR T cells on day 7 after infusion are associated with progressive disease and less severe neurotoxicity. Deep profiling demonstrated that this population is non-clonal and manifests hallmark features of T regulatory (TReg) cells. Validation cohort analysis upheld the link between higher CAR TReg cells with clinical progression and less severe neurotoxicity. A model combining expansion of this subset with lactate dehydrogenase levels, as a surrogate for tumor burden, was superior for predicting durable clinical response compared to models relying on each feature alone. These data credential CAR TReg cell expansion as a novel biomarker of response and toxicity after CAR T cell therapy and raise the prospect that this subset may regulate CAR T cell responses in humans.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Good Z, Spiegel JY, Sahaf B, et al. Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy. Nat Med. 2022. PMID: 36097223. doi:10.1038/s41591-022-01960-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。